284 related articles for article (PubMed ID: 31897675)
41. Prospective study of brentuximab vedotin in relapsed/refractory Hodgkin lymphoma patients who are not suitable for stem cell transplant or multi-agent chemotherapy.
Walewski J; Hellmann A; Siritanaratkul N; Ozsan GH; Ozcan M; Chuncharunee S; Goh AS; Jurczak W; Koren J; Paszkiewicz-Kozik E; Wang B; Singh S; Huebner D; Engert A; von Tresckow B
Br J Haematol; 2018 Nov; 183(3):400-410. PubMed ID: 30168134
[TBL] [Abstract][Full Text] [Related]
42. Second autologous stem cell transplantation for relapsed/refractory Hodgkin lymphoma after a previous autograft: a study of the lymphoma working party of the EBMT.
Martínez C; Boumendil A; Romejko-Jarosinska J; Anagnostopoulos A; Faber E; Poiré X; Yakoub-Agha I; Akhtar S; Gurman G; Pavone V; Halaburda K; Sousa AB; Ghesquières H; Finel H; Khvedelidze I; Montoto S; Sureda A
Leuk Lymphoma; 2020 Dec; 61(12):2915-2922. PubMed ID: 32654552
[TBL] [Abstract][Full Text] [Related]
43. Long-term outcome of autologous stem-cell transplantation in relapsed or refractory Hodgkin's lymphoma.
Sirohi B; Cunningham D; Powles R; Murphy F; Arkenau T; Norman A; Oates J; Wotherspoon A; Horwich A
Ann Oncol; 2008 Jul; 19(7):1312-1319. PubMed ID: 18356139
[TBL] [Abstract][Full Text] [Related]
44. Allogeneic transplantation improves the overall and progression-free survival of Hodgkin lymphoma patients relapsing after autologous transplantation: a retrospective study based on the time of HLA typing and donor availability.
Sarina B; Castagna L; Farina L; Patriarca F; Benedetti F; Carella AM; Falda M; Guidi S; Ciceri F; Bonini A; Ferrari S; Malagola M; Morello E; Milone G; Bruno B; Mordini N; Viviani S; Levis A; Giordano L; Santoro A; Corradini P;
Blood; 2010 May; 115(18):3671-7. PubMed ID: 20220116
[TBL] [Abstract][Full Text] [Related]
45. [Treatment of Relapsed and Refractory Hodgkin Lymphoma - Recommendations of the Czech Hodgkin Lymphoma Study Group].
Móciková H; Marková J; Gahérová Ľ; Král Z; Sýkorová A; Belada D; Procházka V; Martinková L; Papajík T; Kozák T
Klin Onkol; 2016; 29(5):342-346. PubMed ID: 27739312
[TBL] [Abstract][Full Text] [Related]
46. [High-dose chemotherapy and autologous stem cell transplantation for refractory and relapsing Hodgkin's disease as first-line therapy-- studies at Sheba Medical Center--Tel Hashomer].
Avigdor A; Hardan I; Shpilberg O; Raanani P; Grotto I; Ben-Bassat I
Harefuah; 2000 Sep; 139(5-6):174-9, 248, 247. PubMed ID: 11062945
[TBL] [Abstract][Full Text] [Related]
47. Brentuximab vedotin in relapsed/refractory Hodgkin lymphoma post-autologous stem cell transplant: a cost-effectiveness analysis in Scotland.
Parker C; Woods B; Eaton J; Ma E; Selby R; Benson E; Engstrom A; Sajosi P; Briggs A; Bonthapally V
J Med Econ; 2017 Jan; 20(1):8-18. PubMed ID: 27472034
[TBL] [Abstract][Full Text] [Related]
48. Patterns of Failure and Survival Outcomes after Total Lymphoid Irradiation and High-Dose Chemotherapy with Autologous Stem Cell Transplantation for Relapsed or Refractory Classical Hodgkin Lymphoma.
Paudel N; Schulze D; Gentzler RD; Evens AM; Helenowski I; Dillehay G; Frankfurt O; Mehta J; Donnelly ED; Gordon LI; Winter JN; Mittal BB
Int J Radiat Oncol Biol Phys; 2019 Jun; 104(2):436-446. PubMed ID: 30763660
[TBL] [Abstract][Full Text] [Related]
49. Reduced-intensity conditioning (RIC) and allogeneic stem cell transplantation (allo-SCT) for relapsed/refractory Hodgkin lymphoma (HL) in the brentuximab vedotin era: favorable overall and progression-free survival (OS/PFS) with low transplant-related mortality (TRM).
Clin Adv Hematol Oncol; 2014 Feb; 12(2 Suppl 6):15-7. PubMed ID: 24870877
[No Abstract] [Full Text] [Related]
50. Autologous and allogeneic stem-cell transplantation for transformed follicular lymphoma: a report of the Canadian blood and marrow transplant group.
Villa D; Crump M; Panzarella T; Savage KJ; Toze CL; Stewart DA; MacDonald DA; Buckstein R; Lee C; Alzahrani M; Rubinger M; Foley R; Xenocostas A; Sabloff M; Muccilli A; Chua N; Couture F; Larouche JF; Cohen S; Connors JM; Ambler K; Al-Tourah A; Ramadan KM; Kuruvilla J
J Clin Oncol; 2013 Mar; 31(9):1164-71. PubMed ID: 23401459
[TBL] [Abstract][Full Text] [Related]
51. Brentuximab vedotin followed by allogeneic transplantation as salvage regimen in patients with relapsed and/or refractory Hodgkin's lymphoma.
Garciaz S; Coso D; Peyrade F; Fürst S; Duran S; Chetaille B; Brenot-Rossi I; Devillier R; Granata A; Blaise D; Bouabdallah R
Hematol Oncol; 2014 Dec; 32(4):187-91. PubMed ID: 24301099
[TBL] [Abstract][Full Text] [Related]
52. [Follicular lymphoma: first - line selection criteria of treatment].
Nesterova ES; Kravchenko SK; Kovrigina AM; Gemdzhian EG; Plastinina LV; Babaeva FE; Obukhova TN; Magomedova AU; Gaponova TV; Kremenetskaya AM; Vorobyev AI
Ter Arkh; 2019 Aug; 91(8):75-83. PubMed ID: 32598757
[TBL] [Abstract][Full Text] [Related]
53. Long-term results of autologous stem cell transplantation for primary refractory or relapsed Hodgkin's lymphoma.
Majhail NS; Weisdorf DJ; Defor TE; Miller JS; McGlave PB; Slungaard A; Arora M; Ramsay NK; Orchard PJ; MacMillan ML; Burns LJ
Biol Blood Marrow Transplant; 2006 Oct; 12(10):1065-72. PubMed ID: 17084370
[TBL] [Abstract][Full Text] [Related]
54. Serum thymus and activation-regulated chemokine level monitoring may predict disease relapse detected by PET scan after reduced-intensity allogeneic stem cell transplantation in patients with Hodgkin lymphoma.
Farina L; Rezzonico F; Spina F; Dodero A; Mazzocchi A; Crippa F; Alessi A; Dalto S; Viviani S; Corradini P
Biol Blood Marrow Transplant; 2014 Dec; 20(12):1982-8. PubMed ID: 25240818
[TBL] [Abstract][Full Text] [Related]
55. [Brentuximab vedotin treatment in patients with relapsed or refractory Hodgkin lymphoma. A Hungarian retrospective study].
Molnár Z; Pinczés LI; Piukovics K; Istenes I; Wolf K; Csukly Z; Szomor Á; Illés Á; Miltényi Z
Orv Hetil; 2017 Oct; 158(41):1630-1634. PubMed ID: 29025292
[TBL] [Abstract][Full Text] [Related]
56. The role of hematopoietic stem cell transplantation for relapsed and refractory Hodgkin lymphoma.
Kako S; Izutsu K; Kato K; Kim SW; Mori T; Fukuda T; Kobayashi N; Taji H; Hashimoto H; Kondo T; Sakamaki H; Morishima Y; Kato K; Suzuki R; Suzumiya J;
Am J Hematol; 2015 Feb; 90(2):132-8. PubMed ID: 25382792
[TBL] [Abstract][Full Text] [Related]
57. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
58. Relapse or refractory Hodgkin lymphoma: determining risk of relapse or progression after autologous stem-cell transplantation.
Bentolila G; Pavlovsky A
Leuk Lymphoma; 2020 Jul; 61(7):1548-1554. PubMed ID: 32148142
[TBL] [Abstract][Full Text] [Related]
59. Five-year survival and durability results of brentuximab vedotin in patients with relapsed or refractory Hodgkin lymphoma.
Chen R; Gopal AK; Smith SE; Ansell SM; Rosenblatt JD; Savage KJ; Connors JM; Engert A; Larsen EK; Huebner D; Fong A; Younes A
Blood; 2016 Sep; 128(12):1562-6. PubMed ID: 27432875
[TBL] [Abstract][Full Text] [Related]
60. High-dose chemotherapy followed by autologous stem cell transplantation for relapsed or refractory Hodgkin lymphoma: prognostic features and outcomes.
Engelhardt BG; Holland DW; Brandt SJ; Chinratanalab W; Goodman SA; Greer JP; Jagasia MH; Kassim AA; Morgan DS; Ruffner KL; Schuening FG; Wolff S; Bitting R; Sulur P; Stein RS
Leuk Lymphoma; 2007 Sep; 48(9):1728-35. PubMed ID: 17786708
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
